Anonymous Client I — Vaccine manufacturer ($3.5B revenue, modernizing clinical development)
The manufacturer ran 20+ active trial sites across 5 countries for their vaccine portfolio. Their technology infrastructure was fragmented — 3 different EDC systems, no unified patient engagement platform, and no remote monitoring capability. Site staff were overwhelmed with manual data entry, and patient retention was declining year-over-year. The CMO had been tasked by the board with implementing decentralized trial capabilities within 12 months.
A vaccine manufacturer needed to modernize their clinical development process with decentralized trial capabilities. Their traditional site-based model was resulting in slow enrollment (averaging 14 months for Phase III trials), limited patient diversity (72% white participants in US trials), and outdated paper-based data collection with 8-12 week data lock delays. A competing vaccine manufacturer had recently launched a decentralized trial that enrolled in 6 months with 45% diversity — creating competitive pressure to modernize.
We designed a comprehensive digital transformation roadmap for decentralized clinical trials, covering technology selection, site enablement, patient engagement platforms, and data integration strategy. Our approach combined technology evaluation (12 vendors across 6 categories), site readiness assessment (20+ sites), patient journey mapping, and ROI modeling. We delivered a phased implementation plan with technology recommendations, change management strategy, and projected ROI.
Current state assessment: Audited existing technology infrastructure, site capabilities, patient engagement processes, and data flows across 20+ trial sites
Technology evaluation: Assessed 12 decentralized trial technology vendors across 6 categories (eDC, eConsent, remote monitoring, wearables, telehealth, patient engagement)
Site readiness analysis: Evaluated 20+ sites for decentralized trial readiness, including technology infrastructure, staff capabilities, and regulatory compliance
Patient journey mapping: Designed patient-centric trial journeys incorporating remote visits, wearable monitoring, and digital consent
Data integration strategy: Designed a unified data architecture integrating eDC, wearables, telehealth, and patient-reported outcomes into a single platform
ROI modeling: Built financial models projecting development cost savings, enrollment acceleration, and data quality improvements
Change management planning: Developed a phased adoption strategy with site training, patient communication, and regulatory engagement
We delivered a 3-phase digital transformation roadmap: (1) Phase 1 (Months 1-4): Deploy unified eDC with eConsent and remote monitoring at 5 pilot sites, (2) Phase 2 (Months 5-8): Expand to all 20+ sites with wearable integration and telehealth capabilities, (3) Phase 3 (Months 9-12): Full decentralized trial capability with AI-powered monitoring and predictive enrollment analytics. We recommended a primary technology stack of 4 integrated platforms and projected 35% enrollment acceleration, 28% diversity improvement, and 22% development cost reduction.
Phase 1 (Weeks 1-5): Current state assessment and technology vendor evaluation
Phase 2 (Weeks 4-10): Site readiness analysis and patient journey mapping
Phase 3 (Weeks 8-14): Data integration architecture design and ROI modeling
Phase 4 (Weeks 12-18): Phased implementation roadmap with change management plan
Phase 5 (Weeks 18-22): Final recommendations, vendor selection support, and pilot site preparation
| Metric | Before | After | Impact |
|---|---|---|---|
| Average Enrollment Timeline | 14 months | 9 months | 35% acceleration through remote visits and expanded site network |
| Patient Diversity (US) | 28% non-white | 36% non-white | +28% improvement through community-based site expansion |
| Data Lock Timeline | 8-12 weeks | 2-3 weeks | Real-time data capture and automated queries reduced lock time by 75% |
| Patient Retention Rate | 78% | 91% | Digital engagement tools and reduced site visits improved retention |
| Development Cost per Trial | $45M | $35M | 22% cost reduction through reduced site visits, faster enrollment, and automated monitoring |
“Our competitor enrolled a Phase III vaccine trial in 6 months while we were still at 14 months. Medifirm's digital transformation roadmap didn't just give us technology recommendations — it gave us a complete operating model change. We're now enrolling in 9 months with better diversity and data quality.”
Chief Medical Officer
Anonymous Client I
Forecast
Decentralized trial implementation projected to reduce development costs by 22% over 3 years through faster enrollment, reduced site visits, and improved data quality.
Every engagement starts with understanding your unique strategic challenge. Partner with Medifirm to transform data into decisions.